The introduction of biotherapies has dramatically changed the care and evolution of children with juvenile idiopathic arthritis. These biotherapies, directed against tumor necrosis factor (TNF)...

On average, 40% of juvenile idopathic arthritis remain active in adulthood, with differences according to the type (oligoarticular, polyarticular, enthesitis related arthiritis). It is essential to...